Editor's NoteArtificial intelligence (AI) is fundamentally shaking up the landscape of the pharmaceutical and biotechnology markets. NVIDIA's partnership with global big pharma Eli Lilly to invest $1 billion (approximately 1.499 trillion won) in AI-driven drug development stands as a symbol of a paradigm shift that is rewriting the historical narrative of the biopharma industry with entirely new rules. The territory of AI, once limited to candidate substance discovery, is now expanding to encompass the entire drug development cycle—including sophisticated clinical trial design, optimal patient group selection, and real-time manufacturing process control—fundamentally restructuring the economics of the industry itself. The average time required for candidate discovery has been reduced from three to four years to as little as one year. Leveraging its capabilities in three-dimensional understanding of target proteins and improved toxicity prediction accuracy, AI has raised the Phase 1 clinical trial success rate from the traditional 40–65% range to 80–90%. For companies facing the so-called "valley of death" in drug development, the efficiency of AI in reducing the astronomical sunk costs associated with early-stage failure represents the only breakthrough. Through the special series "K-Bio Faces the AI Challenge," The Asia Business Daily will examine how the global new drug development landscape has been reorganized into a high-speed race in 2026, and explore the strategies for the survival and leap forward of Korea's bioindustry.

As artificial intelligence (AI) is rapidly being adopted in the drug development process, experts say Korea’s bioindustry must also adjust its strategy. Rather than jumping directly into the AI technology race, it is considered more realistic for Korea to leverage its strengths in medical data and clinical infrastructure to enhance the efficiency of drug development.


Global AI drug development companies are also focusing their strategies on securing data. This involves collaborating with hospital networks to obtain patient clinical data or accumulating experimental data through joint research with pharmaceutical companies. Rather than developing drugs independently, AI companies are rapidly adopting platform-based research structures that integrate pharmaceutical firms, hospitals, and research institutions.


[K-Bio on the AI Testbed]⑤A Platform Structure Linking Companies, Hospitals, and Institutions Is Needed View original image

A representative example is Isomorphic Labs, an AI drug development company spun off from Google DeepMind. According to the bioindustry as of March 18, the company has signed joint research agreements worth up to $1.7 billion (approximately 2.548 trillion won) each with Eli Lilly and Novartis, and is building an AI-based drug design platform. This cooperative model involves the AI company providing algorithms while the pharmaceutical partner contributes clinical development experience. French AI biotech company Aqemia is also collaborating with hospital networks to conduct AI-driven drug research based on patient clinical data. In partnership with Roche, it utilizes actual patient data for AI model training.


Experts believe that the AI drug development race has moved beyond a mere competition of technologies. Dohyun Kim, senior researcher at the Korea Institute of Science and Technology Evaluation and Planning (KISTEP), stated in the report "Trends in AI-Based Drug Development Technology" that, "The AI drug development competition is not about algorithms, but about ecosystems based on data and research infrastructure," adding, "It is crucial for hospitals, pharmaceutical companies, and AI firms to share data and connect research efforts."


Given these trends, Korea's strategic direction becomes clear. Seungkyu Lee, Vice Chairman of the Korea Biotechnology Industry Organization, said, "Korea has a significant advantage in medical data within the global market," and emphasized, "We must consider how to use this data more efficiently in drug development."


Korea’s medical data infrastructure is highly regarded internationally. The Organisation for Economic Co-operation and Development (OECD), in a report analyzing Korea's healthcare data system, evaluated that Korea's health insurance claims data is among the world's best in terms of scope, granularity, and timeliness. Another distinguishing feature is that nationwide healthcare usage records are accumulated based on a single health insurance system.


Within the industry, there is a growing call to establish governance centered around a national-level control tower. Since AI drug development requires the integration of data, clinical trials, and industry research, it is necessary to design R&D support and data utilization policies in a unified manner at the industry ecosystem level. Vice Chairman Lee also noted, "AI-powered drug development is an area where data, clinical trials, and industry research must move together," adding, "Government support should also be designed as an ecosystem-level strategy."


Yuntaek Jung, President of the Pharmaceutical Industry Strategy Research Institute, stated, "Given the significant unmet medical needs recognized by agencies such as the U.S. Food and Drug Administration (FDA), new modalities or candidate discovery using AI can offer a substantial competitive edge," and added, "As this is an early-stage market, government-driven initiatives in R&D investment, talent development, and overseas expansion are required."


The government is positioning AI-driven drug development as a core sector for the next-generation bioindustry and is significantly expanding related policies. On March 11, the Ministry of Science and ICT launched the national project "K-Moonshot," which aims to integrate AI across scientific and technological research to accelerate drug development by a factor of 10, building a collaborative network with more than 160 companies. The Ministry of Health and Welfare and the Ministry of Food and Drug Safety are also accelerating the establishment of the "K-Clinical Platform," which supports the use of clinical data and digital-based clinical trials. Furthermore, the National Bio-Innovation Committee, a pan-governmental control tower under the Prime Minister, was officially launched on March 3, which is expected to further systematize the development of strategies and coordination of projects across the entire bioindustry, including healthcare.


The key issue is whether these government initiatives can overcome the traditional siloed approach of departmental administration and yield tangible results. AI-driven drug development requires seamless integration of data, clinical trials, and industry research; if data building, R&D, and clinical support policies continue to be pursued separately as in the past, their effectiveness as industry ecosystem-level strategies will be limited. This is why there are calls for the National Bio-Innovation Committee to move beyond being a declarative body and to secure governance that unites inter-ministerial policies.


For AI drug development and bio companies, dispelling market skepticism through actual clinical entry and concrete business results is also critical. Taeyong Park, Vice President of Galux, said, "In the past, many AI platform companies emphasized only their technological vision, which led to accumulated market fatigue," and stressed, "Now is the time to deliver genuinely competitive drug candidates and demonstrate measurable business achievements—such as global partnerships—to prove their value." Taeyoung Yoon, CEO of Proteina, added, "If you only make claims about being able to do anything without tangible results, it means nothing. To turn skepticism in the industry and capital markets into confidence, at least one or two new drug pipelines designed or recreated by AI must quickly enter actual clinical stages."



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing